Strong FRα immunohistochemical (IHC) staining is highly associated with poor outcome in breast cancer patients [17], and while approximately 30 % of breast cancers express FRα, 70–80 % of stage IV metastatic TNBC tumors express FRα across multiple subtypes [4]. The gene discussed is FOLR1; the disease is breast cancer.